Clinical Trials

The Department of Neurology is actively involved in clinical trials to determine the effectiveness of new medications to treat neuromuscular diseases and disorders. If you are interested in receiving additional information or participating in a trial, please e-mail or call the persons listed below. Please note that enrollment is currently closed for some of the trials.

Movement Disorders / Parkinson's Disease - Ongoing Trials
Movement Disorders / Parkinson's Disease - Completed Trials
Multiple Sclerosis (MS) - Ongoing Trials
Multiple Sclerosis (MS) - Completed Trials; data being analyzed
Multiple Sclerosis (MS) - Completed Trials; for historical reference
Neuro-Oncology - Ongoing Trials
Stroke - Ongoing Trials
Stroke - Completed Trials; data being analyzed
Return to the main Patient Care Page

Neuro-Oncology - Ongoing Trials

A Dose Escalation Study of Locally Administered OncoGel (paclitaxel) in Subjects with Recurrent Glioma
	Enrollment is OPEN Non-randomized, non-placebo, multi-center trial.
	The purpose of this study is to: Determine the safety and tolerability of OncoGel delivered intracranially at the tumor site after resection for recurrent glioma. Evaluate the potential treatment effects of OncoGel on tumor response, survival, and performance status.
	Eligibility Criteria: 18 to 70 years old Progressive unilateral, unifocal, supratentorial malignant glioma
	Principle Investigator:	Maciej Lesniak, MD

Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
	Enrollment is OPEN Non-randomized, non-placebo, multi-center trial.
	The purpose of this study is to: Evaluate the effect on survival as well as the response on MRI of Avastin in combination with temozolomide in newly diagnosed glioblastomas. Evaluate the safety of this combination of therapies. Evaluate the duration of potential response to these therapies.
	Eligibility Criteria: At least 18 years old Newly diagnosed glioblastoma Supratentorial location of tumor
	Principle Investigator:	M. Kelly Nicholas MD PhD

CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme
	Enrollment is OPEN Non-randomized, non-placebo, multi-center trial.
	The purpose of this study is to: Evaluate the effect on survival using an EGFRvIII vaccine in combination with temozolomide. Evaluate the safety and tolerability of an EGFRvIII vaccine in combination with temozolomide.
	Eligibility Criteria: At least 18 years old Minimal residual tumor after surgery Newly diagnosed glioblastoma
	Principle Investigator:	Maciej Lesniak, MD

Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients with Progressive and/or Recurrent Malignant Glioma
	Enrollment is on Hold Non-randomized, non-placebo, multi-center trial.
	The purpose of this study is to: Evaluate the safety of multiple IV doses of 131I-TM601. Evaluate the efficacy of multiple IV doses of 131I-TM601.
	Eligibility Criteria: At least 18 years old Recurrent glioma Anaplastic astrocytoma, anaplastic oligodendroglioma, or glioblastoma which is progressive radiation +/- chemotherapy
	Principle Investigator:	Stephen Chmura, MD PhD

Trial of Bevacizumab with Irinotecan or Bevacizumab with Temozolomide in Recurrent Glioblastoma
	Enrollment is OPEN Non-randomized, non-placebo, multi-center trial.
	The purpose of this study is to: Evaluate the effect of bevacizumab and irinotecan on survival. Evaluate the tolerability of bevacizumab and temozolomide as well as bevacizumab and irinotecan. Evaluate the effect of bevacizumab and temozolomide on survival.
	Eligibility Criteria: At least 18 years old Recurrent glioblastoma
	Principle Investigator:	Stephen Chmura, MD PhD